165 related articles for article (PubMed ID: 33054119)
1. A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade.
Miller PG; Sperling AS; Gibson CJ; Pozdnyakova O; Wong WJ; Manos MP; Buchbinder EI; Hodi FS; Ebert BL; Davids MS
Haematologica; 2021 Feb; 106(2):651-654. PubMed ID: 33054119
[No Abstract] [Full Text] [Related]
2. NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
Alderuccio JP; Lossos IS
Leuk Lymphoma; 2022 Feb; 63(2):279-290. PubMed ID: 34586000
[TBL] [Abstract][Full Text] [Related]
3. Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma.
Robinson AC; Nachar VR
J Oncol Pharm Pract; 2020 Jul; 26(5):1248-1253. PubMed ID: 31766968
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema.
Motosue MS; Howard MT; Butterfield JH
Ann Allergy Asthma Immunol; 2016 May; 116(5):472-3. PubMed ID: 27017557
[No Abstract] [Full Text] [Related]
5. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
6. Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report.
Arcaini L; Sacchi P; Jemos V; Lucioni M; Rumi E; Dionigi P; Paulli M
Ann Hematol; 2009 Apr; 88(4):379-81. PubMed ID: 18709501
[No Abstract] [Full Text] [Related]
7. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
8. [Rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma: a case report and literature review].
Huang AJ; Ni X; Fu WJ; Zhang Y; Tang GS; Wang JM
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):338-342. PubMed ID: 33979980
[No Abstract] [Full Text] [Related]
9. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
Wu L; Tian C; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
[TBL] [Abstract][Full Text] [Related]
10. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
11. A new taxonomy for splenic marginal zone lymphoma.
Deaglio S; Vaisitti T
Blood; 2022 Feb; 139(5):644-645. PubMed ID: 35113148
[No Abstract] [Full Text] [Related]
12. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis.
Niscola P; Palumbo R; Scaramucci L; Tendas A; Cupelli L; Giovannini M; Piccioni D; Dentamaro T; Perrotti AP; de Fabritiis P
Cancer Chemother Pharmacol; 2009 Mar; 63(4):759-60. PubMed ID: 18500519
[No Abstract] [Full Text] [Related]
13. Pseudo-faggot cells in splenic marginal zone lymphoma.
Wilson J
Br J Haematol; 2023 Apr; 201(1):7. PubMed ID: 36606572
[No Abstract] [Full Text] [Related]
14. Effective management strategies for patients with marginal zone lymphoma.
Rosand CB; Valla K; Flowers CR; Koff JL
Future Oncol; 2018 May; 14(12):1213-1222. PubMed ID: 29260925
[TBL] [Abstract][Full Text] [Related]
15. Epidermotropic CXCR3 positive marginal zone lymphoma: a distinctive clinical histopathological entity potentially originating in the skin; it does not always indicate splenic marginal zone lymphoma.
Magro CM; Momtahen S; Coleman M; Grossman ME
Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450275
[TBL] [Abstract][Full Text] [Related]
16. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
Kalpadakis C; Pangalis GA; Sachanas S; Tsirkinidis P; Kontopidou FN; Moschogiannis M; Yiakoumis X; Koulieris E; Dimopoulou MN; Kokkoris SI; Kyrtsonis MC; Siakantaris MP; Tsourouflis G; Korkolopoulou P; Rontogianni D; Tsaftaridis P; Plata E; Papadaki HA; Panagiotidis P; Angelopoulou MK; Vassilakopoulos TP
Blood; 2018 Aug; 132(6):666-670. PubMed ID: 29914978
[No Abstract] [Full Text] [Related]
17. Bonfiglio F, Bruscaggin A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732-747.
Blood; 2023 Mar; 141(13):1647. PubMed ID: 36995700
[No Abstract] [Full Text] [Related]
18. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
19. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
20. Severe Protein-Losing Enteropathy Due to an Indolent Splenic Lymphoma: Case Report and Review of the Literature.
Naymagon L; Ward S; Naymagon S; Navada S
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e165-e168. PubMed ID: 30685184
[No Abstract] [Full Text] [Related]
[Next] [New Search]
